Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel O Persky

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Blood|January 13, 2018
Limited-stage DLBCL: it's patient selectionDaniel O Persky
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
Treatment of Early (Limited)-Stage DLBCLAbhijeet Kumar, Daniel O Persky
Current Opinion in Oncology|July 14, 2009
Localized large cell lymphoma: is there any need for radiation therapy?Daniel O Persky, Thomas P Miller
British Journal of Haematology|November 20, 2020
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignanciesAlexey V Danilov, Daniel O Persky
Current Treatment Options in Oncology|July 18, 2016
Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?Abhijeet Kumar, Srinath Sundararajan, Soham Puvvada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2020
Reply to E. Hawkes et alDaniel O Persky, Sonali M Smith, Michael L LeBlanc, et al.
Annals of Hematology|July 19, 2021
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017)Neda Alrawashdh, Joann Sweasy, Brian Erstad, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 6, 2021
Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experienceLogan Moore, Trace Bartels, Daniel O Persky, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival CurvesNeda Alrawashdh, Daniel O Persky, Ali McBride, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 10, 2022
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic LeukemiaNeda Alrawashdh, Ali McBride, Brian Erstad, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Blood|January 13, 2018
Limited-stage DLBCL: it's patient selectionDaniel O Persky
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
Treatment of Early (Limited)-Stage DLBCLAbhijeet Kumar, Daniel O Persky
Current Opinion in Oncology|July 14, 2009
Localized large cell lymphoma: is there any need for radiation therapy?Daniel O Persky, Thomas P Miller
British Journal of Haematology|November 20, 2020
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignanciesAlexey V Danilov, Daniel O Persky
Current Treatment Options in Oncology|July 18, 2016
Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?Abhijeet Kumar, Srinath Sundararajan, Soham Puvvada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2020
Reply to E. Hawkes et alDaniel O Persky, Sonali M Smith, Michael L LeBlanc, et al.
Annals of Hematology|July 19, 2021
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017)Neda Alrawashdh, Joann Sweasy, Brian Erstad, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 6, 2021
Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experienceLogan Moore, Trace Bartels, Daniel O Persky, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival CurvesNeda Alrawashdh, Daniel O Persky, Ali McBride, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 10, 2022
Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic LeukemiaNeda Alrawashdh, Ali McBride, Brian Erstad, et al.
Pageof 5